<DOC>
	<DOCNO>NCT00005110</DOCNO>
	<brief_summary>Long term use bronchodilator CF beneficial improvement pulmonary function symptom . This study investigate long-term benefit administration drug Salmeterol , bronchodilator . Salmeterol compare albuterol placebo . The medication inhale twice day 6 month .</brief_summary>
	<brief_title>A Multi-Centered Study Long-Term Effect Salmeterol Albuterol Cystic Fibrosis</brief_title>
	<detailed_description>Patients diagnose cystic fibrosis 5 year 45 year age eligible . Subjects randomize 1 3 group . One group get Salmeterol multi-dose inhaler ( MDI ) 2 puff 2 time day , one group get albuterol MDI 2 puff 2 time day get placebo MDI 2 puff 2 time day . Height weight along pulmonary function test vital sign monitor begin study Visits 2 , 3 , 4 . Peak flow monitoring do morning study medication home . A daily diary keep measurement . Subjects see research center visit 1,2,3 , 4 . Telephone contact do Day 15 , 60 , 120 , 150 . Individual outcomes include potential increase pulmonary function test decrease frequency pulmonary exacerbation , hospitalization , usage antibiotic .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Ability perform reproducible spirometry FEVI &gt; 50 % &lt; 90 % ( Knudsen ) A CF pulmonary exacerbation within last year FEVI &lt; 80 % At least one delta f508 allele CF mutation analysis Ability demonstrate use inhale medicine FEVI PEFR monitor Written inform consent Negative serum pregnancy test enrollment</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2001</verification_date>
</DOC>